Home » Stocks » IKNA

Ikena Oncology, Inc. (IKNA)

Stock Price: $13.69 USD -0.03 (-0.22%)
Updated Jun 17, 2021 1:31 PM EDT - Market open
Market Cap 577.16M
Revenue (ttm) 9.44M
Net Income (ttm) n/a
Shares Out 3.85M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 17
Last Price $13.69
Previous Close $13.72
Change ($) -0.03
Change (%) -0.22%
Day's Open 13.76
Day's Range 13.51 - 14.39
Day's Volume 43,970
52-Week Range 13.00 - 37.61

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BOSTON--(BUSINESS WIRE)--Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation and spread of cancer, ...

3 weeks ago - Business Wire

BOSTON--(BUSINESS WIRE)--Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation and spread of cancer, ...

1 month ago - Business Wire

BOSTON--(BUSINESS WIRE)--Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and s...

2 months ago - Business Wire

Ikena Oncology, Inc. (NASDAQ: IKNA), 180 Life Sciences Corp. (NASDAQ: ATNF) and Evelo Biosciences, Inc. (NASDAQ: EVLO) are among the major biopharma movers of Monday. Ikena Oncology Gains On Fund Buying...

Other stocks mentioned: ATNF, EVLO
2 months ago - Benzinga

BOSTON--(BUSINESS WIRE)--Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and s...

2 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Ikena Oncology, Inc. (“Ikena”), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer...

2 months ago - Business Wire

Ikena Oncology, a phase 1 oncology biotech developing small molecule inhibitor therapies, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

3 months ago - NASDAQ

Ikena Oncology, Inc. has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC

About IKNA

Ikena Oncology is a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Our programs focus on key cancer driver pathways that are well-validated in scientific literature but lack approved or effective therapies and therefore have the potential to address high unmet medical needs. By leveraging our deep understanding of discovery chemistry, translational science, and patient-centric drug development, we have built a deep pipeline of wholly owned an... [Read more...]

Industry
Biotechnology
IPO Date
Mar 26, 2021
CEO
Mark Manfredi, Ph.D.
Employees
38
Stock Exchange
NASDAQ
Ticker Symbol
IKNA
Full Company Profile

Financial Performance

In 2020, Ikena Oncology's revenue was $9.19 million, a decrease of -33.15% compared to the previous year's $13.75 million. Losses were -$44.26 million, 163.2% more than in 2019.

Financial Statements